377 related articles for article (PubMed ID: 33475057)
1. TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease.
Furfaro F; Alfarone L; Gilardi D; Correale C; Allocca M; Fiorino G; Argollo M; Zilli A; Zacharopoulou E; Loy L; Roda G; Danese S
Curr Drug Targets; 2021; 22(7):760-769. PubMed ID: 33475057
[TBL] [Abstract][Full Text] [Related]
2. TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis.
Solitano V; Jairath V; Ungaro F; Peyrin-Biroulet L; Danese S
Med; 2024 May; 5(5):386-400. PubMed ID: 38574740
[TBL] [Abstract][Full Text] [Related]
3. TL1A (TNFSF15) and DR3 (TNFRSF25): A Co-stimulatory System of Cytokines With Diverse Functions in Gut Mucosal Immunity.
Valatas V; Kolios G; Bamias G
Front Immunol; 2019; 10():583. PubMed ID: 30972074
[TBL] [Abstract][Full Text] [Related]
4. TL1A as a Potential Local Inducer of IL17A Expression in Colon Mucosa of Inflammatory Bowel Disease Patients.
Ślebioda TJ; Bojarska-Junak A; Stanisławowski M; Cyman M; Wierzbicki PM; Roliński J; Celiński K; Kmieć Z
Scand J Immunol; 2015 Oct; 82(4):352-60. PubMed ID: 26072972
[TBL] [Abstract][Full Text] [Related]
5. Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis.
Hassan-Zahraee M; Ye Z; Xi L; Baniecki ML; Li X; Hyde CL; Zhang J; Raha N; Karlsson F; Quan J; Ziemek D; Neelakantan S; Lepsy C; Allegretti JR; Romatowski J; Scherl EJ; Klopocka M; Danese S; Chandra DE; Schoenbeck U; Vincent MS; Longman R; Hung KE
Inflamm Bowel Dis; 2022 Mar; 28(3):434-446. PubMed ID: 34427649
[TBL] [Abstract][Full Text] [Related]
6. The tumor necrosis factor-like cytokine 1A/death receptor 3 cytokine system in intestinal inflammation.
Bamias G; Jia LG; Cominelli F
Curr Opin Gastroenterol; 2013 Nov; 29(6):597-602. PubMed ID: 24100723
[TBL] [Abstract][Full Text] [Related]
7. Tumor Necrosis Factor-like Cytokine TL1A and Its Receptors DR3 and DcR3: Important New Factors in Mucosal Homeostasis and Inflammation.
Siakavellas SI; Bamias G
Inflamm Bowel Dis; 2015 Oct; 21(10):2441-52. PubMed ID: 26099067
[TBL] [Abstract][Full Text] [Related]
8. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease.
Bamias G; Martin C; Marini M; Hoang S; Mishina M; Ross WG; Sachedina MA; Friel CM; Mize J; Bickston SJ; Pizarro TT; Wei P; Cominelli F
J Immunol; 2003 Nov; 171(9):4868-74. PubMed ID: 14568967
[TBL] [Abstract][Full Text] [Related]
9. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases.
Li Y; Chen J; Bolinger AA; Chen H; Liu Z; Cong Y; Brasier AR; Pinchuk IV; Tian B; Zhou J
Inflamm Bowel Dis; 2021 Nov; 27(Suppl 2):S38-S62. PubMed ID: 34791293
[TBL] [Abstract][Full Text] [Related]
10. Death-Domain-Receptor 3 Deletion Normalizes Inflammatory Gene Expression and Prevents Ileitis in Experimental Crohn's Disease.
Buttó LF; Jia LG; Arseneau KO; Tamagawa H; Rodriguez-Palacios A; Li Z; De Salvo C; Pizarro TT; Bamias G; Cominelli F
Inflamm Bowel Dis; 2019 Jan; 25(1):14-26. PubMed ID: 30295722
[TBL] [Abstract][Full Text] [Related]
11. Study of tumor necrosis factor receptor in the inflammatory bowel disease.
Souza RF; Caetano MAF; Magalhães HIR; Castelucci P
World J Gastroenterol; 2023 May; 29(18):2733-2746. PubMed ID: 37274062
[TBL] [Abstract][Full Text] [Related]
12. Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammation.
Prehn JL; Mehdizadeh S; Landers CJ; Luo X; Cha SC; Wei P; Targan SR
Clin Immunol; 2004 Jul; 112(1):66-77. PubMed ID: 15207783
[TBL] [Abstract][Full Text] [Related]
13. TL1A blocking ameliorates intestinal fibrosis in the T cell transfer model of chronic colitis in mice.
Li H; Song J; Niu G; Zhang H; Guo J; Shih DQ; Targan SR; Zhang X
Pathol Res Pract; 2018 Feb; 214(2):217-227. PubMed ID: 29254800
[TBL] [Abstract][Full Text] [Related]
14. Crohn's disease-associated mucosal factors regulate the expression of TNF-like cytokine 1A and its receptors in primary subepithelial intestinal myofibroblasts and intestinal epithelial cells.
Bamias G; Filidou E; Goukos D; Valatas V; Arvanitidis K; Panagopoulou M; Kouklakis G; Daikos GL; Ladas SD; Kolios G
Transl Res; 2017 Feb; 180():118-130.e2. PubMed ID: 27665176
[TBL] [Abstract][Full Text] [Related]
15. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies.
Ahluwalia B; Moraes L; Magnusson MK; Öhman L
Scand J Gastroenterol; 2018 Apr; 53(4):379-389. PubMed ID: 29523023
[TBL] [Abstract][Full Text] [Related]
16. Effect and Mechanism of TL1A Expression on Epithelial-Mesenchymal Transition during Chronic Colitis-Related Intestinal Fibrosis.
Wenxiu J; Mingyue Y; Fei H; Yuxin L; Mengyao W; Chenyang L; Jia S; Hong Z; Shih DQ; Targan SR; Xiaolan Z
Mediators Inflamm; 2021; 2021():5927064. PubMed ID: 34257516
[TBL] [Abstract][Full Text] [Related]
17. IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein.
Michelsen KS; Thomas LS; Taylor KD; Yu QT; Mei L; Landers CJ; Derkowski C; McGovern DP; Rotter JI; Targan SR
PLoS One; 2009; 4(3):e4719. PubMed ID: 19262684
[TBL] [Abstract][Full Text] [Related]
18. An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease.
Clarke AW; Poulton L; Shim D; Mabon D; Butt D; Pollard M; Pande V; Husten J; Lyons J; Tian C; Doyle AG
MAbs; 2018; 10(4):664-677. PubMed ID: 29436901
[TBL] [Abstract][Full Text] [Related]
19. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
20. Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB).
Romero RK; Magro DO; Queiroz NSF; Damião AOMC; Teixeira FV; Nones RB; Sassaki LY; Saad-Hossne R; Kotze PG
Gastroenterol Hepatol; 2022; 45(7):499-506. PubMed ID: 34634427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
